PULM Pulmatrix, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1574235 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.0%
TTM net income YoY32.3%
TTM EPS YoY32.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-125.1%
Net margin-122.5%
FCF margin-142.4%
EBITDA margin-123.7%
Returns
ROE-71.0%
ROA-43.5%
ROIC (approx.)—
Asset turnover0.36x
Leverage & solvency
Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio5.3%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $7.81M |
| R&D expense | $38,000 | $7.17M |
| SG&A expense | $5.13M | $7.79M |
| Operating income | -$5.17M | -$9.76M |
| Income tax | $0 | — |
| Net income | -$5.16M | -$9.56M |
| EBITDA | — | -$9.66M |
| EPS (basic) | -1.41 | -2.62 |
| EPS (diluted) | -1.41 | -2.62 |
| Weighted avg. shares (diluted) | 3.65M | 3.65M |
| Banking | ||
| Net interest income | — | $467,000 |
| Balance sheet | ||
| Cash & equivalents | $4.09M | $9.52M |
| Current assets | $4.13M | $9.92M |
| Total assets | $4.14M | $9.94M |
| Current liabilities | $329,000 | $929,000 |
| Total liabilities | $329,000 | $996,000 |
| Shareholders' equity | $3.81M | $8.95M |
| Shares outstanding | 3.65M | 3.65M |
| Cash flow statement | ||
| Operating cash flow | -$5.43M | -$10.72M |
| Capital expenditure | — | $398,000 |
| Free cash flow | — | -$11.11M |
| Investing cash flow | — | -$398,000 |
| Depreciation & amortization | — | $106,000 |
| Stock-based compensation | $25,000 | $511,000 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.